3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
15
Lymphoma, Follicular
12
Lymphoma, Large B-Cell, Diffuse
11
Lymphoma, Non-Hodgkin
10
Lymphoma
10
Lymphoma, Mantle-Cell
7
Recurrence
5
Lymphoma, B-Cell, Marginal Zone
5
Neoplasms
4
Lymphoma, B-Cell
4
Leukemia, B-Cell
3
Neoplasm, Residual
2
Burkitt Lymphoma
2
Mature B-Cell Malignancies
1
Lymphatic Diseases
1
Leukemia, Hairy Cell
1
Leukemia
1
Heart Failure
1
Dendritic Cell Sarcoma, Interdigitating
1
Cytokine Release Syndrome
1
Interventions
Gemcitabine
29
pembrolizumab
20
Cisplatin
20
Magnetic Resonance Spectroscopy
17
Specimen Handling
16
Mitomycin
10
enfortumab vedotin
9
durvalumab
9
Cystoscopy
9
avelumab
8
Nivolumab
8
Fluorouracil
8
Carboplatin
8
Radiation
7
Cystectomy
6
atezolizumab
5
Transurethral Resection of Bladder
5
Radiotherapy
5
Mitozytrex
5
Docetaxel
5
Biopsy
5
tremelimumab
4
sacituzumab govitecan
4
erdafitinib
4
dehydroftorafur
4
Platinum
4
Immunoglobulin G
4
Disulfides
4
1,2-diaminocyclohexaneplatinum II citrate
4
disitamab vedotin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
obinutuzumab
×
90 days
×
Clear all
No trials found.